Efficacy and safety of upadacitinib for 16-week extended induction and 52-week maintenance therapy in patients with moderately to severely active ulcerative colitis.
Panaccione R, Danese S, Zhou W, Klaff J, Ilo D, Yao X, Levy G, Higgins PDR, Loftus EV Jr, Chen S, Gonzalez YS, Leonard C, Hébuterne X, Lindsay JO, Cao Q, Nakase H, Colombel JF, Vermeire S.
Panaccione R, et al. Among authors: loftus ev jr.
Aliment Pharmacol Ther. 2024 Feb;59(3):393-408. doi: 10.1111/apt.17816. Epub 2023 Nov 27.
Aliment Pharmacol Ther. 2024.
PMID: 38010661